- Home
- CXT vs NAMS Comparison
CXT vs NAMS Comparison
Compare CXT & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CXT | NAMS |
|---|---|---|
| Founded | 1855 | 2019 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Office Equipment/Supplies/Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 3.5B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | CXT | NAMS |
|---|---|---|
| Price | $56.07 | $34.37 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 8 |
| Target Price | ★ $76.75 | $47.38 |
| AVG Volume (30 Days) | 500.8K | ★ 661.5K |
| Earning Date | 02-11-2026 | 02-25-2026 |
| Dividend Yield | ★ 1.28% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.68 | N/A |
| Revenue | ★ $1,578,900,000.00 | $35,243,000.00 |
| Revenue This Year | $10.77 | N/A |
| Revenue Next Year | $6.68 | $10.46 |
| P/E Ratio | $19.77 | ★ N/A |
| Revenue Growth | ★ 9.30 | 4.91 |
| 52 Week Low | $41.54 | $14.06 |
| 52 Week High | $69.00 | $42.00 |
Technical Indicators
Market Signals| Indicator | CXT | NAMS |
|---|---|---|
| Relative Strength Index (RSI) | 64.73 | 49.87 |
| Support Level | $51.53 | $31.77 |
| Resistance Level | $53.68 | $33.80 |
| Average True Range (ATR) | 1.31 | 1.42 |
| MACD | 0.44 | 0.16 |
| Stochastic Oscillator | 94.41 | 62.87 |
Price Performance
Historical ComparisonAbout CXT Crane NXT Co.
Crane NXT Co is a industrial technology company that provides proprietary and trusted technology solutions to secure, detect, and authenticate what matters to its customers. It is a pioneer in proprietary micro-optics technology for securing physical products, and its sophisticated electronic equipment and associated software leverages proprietary core capabilities with detection and sensing technologies. The company operates in two segments which are Crane Payment Innovations (CPI) and Security and Authentication Technologies.
About NAMS NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.